Basit öğe kaydını göster

Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database

dc.contributor.authorArikan, Rukiye
dc.contributor.authorYekeduz, Emre
dc.contributor.authorErturk, Ismail
dc.contributor.authorTural, Deniz
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorKarakaya, Serdar
dc.contributor.authorHizal, Mutlu
dc.contributor.authorArslan, Cagatay
dc.contributor.authorTaban, Hakan
dc.contributor.authorKucukarda, Ahmet
dc.contributor.authoroztas, Nihan Senturk
dc.contributor.authorSever, ozlem Nuray
dc.contributor.authorUcar, Gokhan
dc.contributor.authorCan, Orcun
dc.contributor.authorNahit Sendur, Mehmet Ali
dc.contributor.authorDemirci, Umut
dc.contributor.authorKILIÇKAP, SAADETTİN
dc.contributor.authorÇİÇİN, İRFAN
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorozguroglu, Mustafa
dc.contributor.authorÜRÜN, YÜKSEL
dc.date.accessioned2021-12-10T11:24:32Z
dc.date.available2021-12-10T11:24:32Z
dc.date.issued2021
dc.identifier.citationYekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., Arikan R., Arslan C., Taban H., Kucukarda A., et al., "Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database", FUTURE ONCOLOGY, cilt.17, sa.35, ss.4861-4869, 2021
dc.identifier.issn1479-6694
dc.identifier.othervv_1032021
dc.identifier.otherav_7bd1cad0-1552-46e0-ab68-52aac9fbc5df
dc.identifier.urihttp://hdl.handle.net/20.500.12627/171840
dc.identifier.urihttps://doi.org/10.2217/fon-2021-0717
dc.description.abstractLay abstract Nivolumab is an immune checkpoint inhibitor (ICI) that blocks the communication between T cells and cancer cells and instead activates T cells to fight against cancer. Metastatic renal cell carcinoma (mRCC) is one of the most susceptible tumors to ICIs. The Checkmate 025 trial showed the efficacy of nivolumab in patients with previously treated mRCC. In this real-world study, 173 patients with mRCC were treated with nivolumab in the second line and beyond. Nivolumab was effective in the real-world setting without additional safety concerns.
dc.language.isoeng
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectOncology
dc.subjectHealth Sciences
dc.subjectONKOLOJİ
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.titleNivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database
dc.typeMakale
dc.relation.journalFUTURE ONCOLOGY
dc.contributor.departmentAnkara Üniversitesi , ,
dc.identifier.volume17
dc.identifier.issue35
dc.identifier.startpage4861
dc.identifier.endpage4869
dc.contributor.firstauthorID2770946


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster